0.93

0.25% -0.0023

SciSparc Ltd (SPRC)

Overview News Price History Why SPRC Down? Discussions Forecast Stock Split

SciSparc Ltd stock is currently priced at $0.93, with a 24-hour trading volume of 21,728. It has seen a -0.25% decreased in the last 24 hours and a -25.60% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.9307 pivot point. If it approaches the $0.9116 support level, significant changes may occur.

Previous Close:

$0.9323

Open:

$0.93

24h Volume:

21,728

Market Cap:

$2.88M

Revenue:

$2.88M

Net Income/Loss:

$-5.12M

P/E Ratio:

-0.00344

EPS:

-269.9888

Net Cash Flow:

1W Performance:

+3.45%

1M Performance:

-25.60%

6M Performance:

-85.12%

1Y Performance:

+63.13%

1D Range:

$0.9051

$0.94

52W Range:

$0.1407

$14.22

SciSparc Ltd Stock (SPRC) Company Profile

Name

SciSparc Ltd

Sector

Healthcare (1204)

Industry

Biotechnology (696)

Phone

972 3 715777

Address

Tower A, 2nd Floor 20 Raul Wallenberg Street, Tel Aviv

Employee

Twitter

Next Earnings Date

Latest SEC Filings

SPRC's Discussions on Twitter

SciSparc Ltd Stock (SPRC) Latest News

Ratio Review: Analyzing SciSparc Ltd (SPRC)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex

The Dwinnex

SciSparc Ltd. Secures European Patent Boost - TipRanks.com - TipRanks

TipRanks

SciSparc secures European patent for antimicrobial method - Investing.com India

Investing.com India

SciSparc Secures Strategic Advantage with Grant of European Patent - GlobeNewswire

GlobeNewswire

SPRC’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

The InvestChronicle

SciSparc secures European patent for antimicrobial method By Investing.com - Investing.com

Investing.com

SciSparc Ltd Stock (SPRC) Financials Data

SciSparc Ltd (SPRC) Revenue 2024

SPRC reported a revenue (TTM) of $2.88 million for the quarter ending December 31, 2023.

SciSparc Ltd (SPRC) Net Income 2024

SPRC net income (TTM) was -$5.12 million for the quarter ending December 31, 2023, a +11.52% increase year-over-year.

SciSparc Ltd (SPRC) Earnings per Share 2024

SPRC earnings per share (TTM) was -$285.27 for the quarter ending December 31, 2023, a -332.77% decline year-over-year.

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. SciSparc Ltd. has collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.